Geulah Livshits
Stock Analyst at Chardan Capital
(1.88)
# 2,954
Out of 4,760 analysts
185
Total ratings
28.25%
Success rate
-7.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Maintains: Buy | $16 | $5.61 | +185.20% | 6 | Mar 7, 2025 | |
| PASG Passage Bio | Maintains: Buy | $7 → $6 | $0.41 | +1,352.78% | 4 | Mar 4, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $30 → $28 | $4.11 | +581.27% | 8 | Mar 4, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $34 → $30 | $3.90 | +669.23% | 11 | Mar 3, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $15 | $1.90 | +689.47% | 3 | Mar 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $62 → $54 | $8.21 | +557.73% | 15 | Feb 28, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $91 → $68 | $9.30 | +631.18% | 13 | Feb 28, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $7 | $1.73 | +304.62% | 12 | Feb 26, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $212 → $218 | $184.88 | +17.91% | 9 | Feb 20, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $94 → $84 | $42.37 | +98.25% | 12 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.92 | - | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 | $1.50 | +766.67% | 9 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 | $0.54 | +3,233.33% | 9 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.47 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $12 | $3.44 | +249.24% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $2.02 | +642.57% | 5 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $2.66 | +839.85% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $11 | $0.60 | +1,730.28% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $1.39 | +331.65% | 5 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $6.10 | +572.13% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $4.45 | +461.80% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.79 | +570.39% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $33.76 | +516.11% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.21 | +1,222.31% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2.5 | $7.02 | -64.39% | 5 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $6.11 | +1,373.00% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.97 | +0.76% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $600 | $0.82 | +73,160.07% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $4.47 | +571.14% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.73 | +106.19% | 1 | Oct 27, 2020 |
Solid Biosciences
Mar 7, 2025
Maintains: Buy
Price Target: $16
Current: $5.61
Upside: +185.20%
Passage Bio
Mar 4, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.41
Upside: +1,352.78%
4D Molecular Therapeutics
Mar 4, 2025
Maintains: Buy
Price Target: $30 → $28
Current: $4.11
Upside: +581.27%
Iovance Biotherapeutics
Mar 3, 2025
Maintains: Buy
Price Target: $34 → $30
Current: $3.90
Upside: +669.23%
Prime Medicine
Mar 3, 2025
Maintains: Buy
Price Target: $15
Current: $1.90
Upside: +689.47%
Rocket Pharmaceuticals
Feb 28, 2025
Maintains: Buy
Price Target: $62 → $54
Current: $8.21
Upside: +557.73%
Intellia Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $91 → $68
Current: $9.30
Upside: +631.18%
Taysha Gene Therapies
Feb 26, 2025
Maintains: Buy
Price Target: $7
Current: $1.73
Upside: +304.62%
Krystal Biotech
Feb 20, 2025
Maintains: Buy
Price Target: $212 → $218
Current: $184.88
Upside: +17.91%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Buy
Price Target: $94 → $84
Current: $42.37
Upside: +98.25%
Jan 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.92
Upside: -
Jan 8, 2025
Maintains: Buy
Price Target: $13
Current: $1.50
Upside: +766.67%
Dec 18, 2024
Maintains: Buy
Price Target: $18
Current: $0.54
Upside: +3,233.33%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.47
Upside: -
Dec 4, 2024
Maintains: Buy
Price Target: $10 → $12
Current: $3.44
Upside: +249.24%
Nov 20, 2024
Maintains: Buy
Price Target: $15
Current: $2.02
Upside: +642.57%
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $25
Current: $2.66
Upside: +839.85%
Nov 7, 2024
Maintains: Buy
Price Target: $17 → $11
Current: $0.60
Upside: +1,730.28%
Apr 5, 2024
Maintains: Buy
Price Target: $11 → $6
Current: $1.39
Upside: +331.65%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $6.10
Upside: +572.13%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $4.45
Upside: +461.80%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.79
Upside: +570.39%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $33.76
Upside: +516.11%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.21
Upside: +1,222.31%
Aug 22, 2022
Maintains: Buy
Price Target: $4 → $2.5
Current: $7.02
Upside: -64.39%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $6.11
Upside: +1,373.00%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.97
Upside: +0.76%
Aug 13, 2021
Maintains: Buy
Price Target: $660 → $600
Current: $0.82
Upside: +73,160.07%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $4.47
Upside: +571.14%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $8.73
Upside: +106.19%